Adrenergic Pharmacology

Correct Answer

C — Non-selective agonist at alpha-1, alpha-2, beta-1, and beta-2 receptors

Rationale

Epinephrine activates all four major adrenergic receptor subtypes — alpha-1, alpha-2, beta-1, and beta-2 — with high potency. This broad receptor profile accounts for its wide range of physiological effects and makes it the drug of choice for anaphylaxis, where simultaneous action on all four subtypes is therapeutically necessary. Phenylephrine has selective alpha-1 activity. Dobutamine is predominantly a beta-1 selective agent. Clonidine is a selective alpha-2 agonist.

Correct Answer

A — Strong alpha-1 and beta-1 activity with minimal beta-2 activity

Rationale

Norepinephrine is the endogenous neurotransmitter of postganglionic sympathetic neurons and acts with high potency at alpha-1 and beta-1 receptors. Its beta-2 receptor activity is minimal at physiological concentrations, which distinguishes it from epinephrine. This receptor profile explains norepinephrine's clinical use as a vasopressor in septic shock — it reliably raises peripheral vascular resistance through alpha-1 activation with cardiac support through beta-1, while minimizing the vasodilatory effects that limit epinephrine at lower doses. Epinephrine, not norepinephrine, has equal potency at all four receptor subtypes. Albuterol is the beta-2 agonist bronchodilator used for asthma. Clonidine is the agent with selective alpha-2 agonist activity that reduces central sympathetic outflow.

Correct Answer

D — Predominantly selective beta-1 agonist used as a positive inotrope

Rationale

Dobutamine is a synthetic catecholamine with predominantly beta-1 adrenergic receptor selectivity. Its primary pharmacological action is positive inotropy — increasing myocardial contractility — making it the inotrope of choice for cardiogenic shock and acute decompensated heart failure when blood pressure is maintained. It has minimal alpha-1 activity and some beta-2 vasodilatory effect, which together reduce cardiac afterload. Epinephrine is the non-selective agonist at all four receptor subtypes. Phenylephrine is the selective alpha-1 vasopressor. Albuterol is the selective beta-2 bronchodilator used for asthma.

Correct Answer

B — Dose-dependent receptor profile: dopamine-1 receptors at low doses, beta-1 at moderate doses, alpha-1 at high doses

Rationale

Dopamine's defining pharmacological feature is its dose-dependent receptor engagement. At low infusion rates, it preferentially activates dopamine-1 receptors in renal and mesenteric vasculature, producing vasodilation. At moderate rates, beta-1 receptor activation becomes dominant, increasing cardiac output. At high rates, alpha-1 vasoconstriction predominates, raising peripheral vascular resistance similarly to norepinephrine. This sequential receptor engagement means the clinical effect of dopamine depends entirely on the infusion rate, and inadvertent dose escalation can shift the therapeutic goal from renal perfusion to vasoconstriction. Dopamine has meaningful alpha-1 activity at high doses, contradicting a pure alpha-1 description. It has both dopaminergic and adrenergic receptor activity at different infusion rates. While dopamine can indirectly release stored norepinephrine, it also acts directly on receptors — neither description captures its full pharmacology.

Correct Answer

A — Norepinephrine

Rationale

Norepinephrine has strong alpha-1 and beta-1 adrenergic receptor activity with minimal beta-2 activity. This receptor profile produces peripheral vasoconstriction (alpha-1) and cardiac stimulation (beta-1) without significant beta-2 mediated vasodilation or bronchodilation. Epinephrine is a non-selective agonist at all four adrenergic receptor subtypes with significant beta-2 activity. Dobutamine is predominantly a beta-1 selective agonist. Dopamine has a dose-dependent receptor profile.

Correct Answer

C — Dopamine

Rationale

Dopamine has a dose-dependent receptor profile that distinguishes it from other catecholamines. At low infusion rates it primarily activates dopamine-1 receptors in renal and mesenteric vasculature, producing vasodilation. At moderate rates it activates beta-1 receptors, increasing cardiac contractility and heart rate. At high infusion rates alpha-1 receptor activation predominates, causing peripheral vasoconstriction. Epinephrine is a non-selective alpha and beta agonist at all doses. Dobutamine is predominantly beta-1 selective. Norepinephrine has strong alpha-1 and beta-1 activity with minimal beta-2 activity.

Correct Answer

B — Reverses bronchospasm and inhibits further mast cell and basophil mediator release

Rationale

Beta-2 receptor activation in the lungs produces bronchial smooth muscle relaxation, directly reversing the bronchospasm component of anaphylaxis. Beta-2 receptors are also expressed on mast cells and basophils, and their activation raises intracellular cyclic adenosine monophosphate, which inhibits degranulation and reduces further release of histamine and other mediators — interrupting the ongoing allergic cascade. Peripheral vasoconstriction is the role of alpha-1 receptor activation. Increased heart rate and contractility are the effects of beta-1 receptor activation. Renal vasoconstriction is mediated by alpha-1 receptors in the renal vasculature, not by beta-2 signaling.

Correct Answer

D — Dobutamine provides predominantly beta-1 inotropic support without the dose-dependent alpha-1 vasoconstriction that can increase afterload with high-dose dopamine

Rationale

Dobutamine's selective beta-1 profile produces positive inotropy and a modest reduction in afterload through mild beta-2 vasodilation, which together increase cardiac output without raising peripheral vascular resistance. Dopamine at higher doses progressively activates alpha-1 receptors, increasing afterload — counterproductive in cardiogenic shock where the failing ventricle is already working against elevated resistance. When the goal is pure inotropic support in a patient with an adequate blood pressure, dobutamine's receptor selectivity makes it the more predictable choice. Tachycardia is an expected adverse effect of dobutamine but is not the basis for preferring it over dopamine when pure inotropic support is the therapeutic goal. Dobutamine lacks dopamine-1 receptor activity. All catecholamines used in the intensive care unit are administered by continuous intravenous infusion and share short plasma half-lives.

Correct Answer

A — Dopamine-1 receptors in renal and mesenteric vasculature, increasing cyclic adenosine monophosphate and producing vasodilation

Rationale

At low infusion rates (roughly 1 to 3 micrograms per kilogram per minute), dopamine selectively activates dopamine-1 receptors, which are Gs-coupled and increase cyclic adenosine monophosphate in vascular smooth muscle, producing vasodilation in the renal and mesenteric beds. This was historically proposed to protect renal function in acutely ill patients, though clinical trials have not confirmed a benefit in terms of reducing acute kidney injury or dialysis requirements. At higher rates, beta-1 and then alpha-1 effects progressively dominate. Beta-2 receptors contribute minimally to low-dose dopamine vasodilation. Presynaptic alpha-2 autoreceptor stimulation reduces norepinephrine release but is not the mechanism responsible for renal vasodilation with dopamine. Beta-1-mediated renin release becomes relevant at moderate infusion rates, not at the low-dose dopaminergic range.

Correct Answer

C — Alpha-1 receptor activation in peripheral vasculature causing intense vasoconstriction

Rationale

At high infusion rates, dopamine's dose-dependent receptor engagement reaches the alpha-1 range, producing intense peripheral vasoconstriction. This raises peripheral vascular resistance, which is therapeutically useful for blood pressure support but can substantially reduce blood flow to the digits, skin, and other peripheral beds, leading to ischemia. This is the same mechanism as high-dose norepinephrine-associated ischemia. Dopamine-1 receptors produce vasodilation rather than vasoconstriction. Beta-2 receptor activation similarly causes vasodilation in peripheral vascular beds. Beta-1-mediated tachycardia increases myocardial oxygen demand but does not produce the peripheral limb ischemia that arises from intense vasoconstriction.

Correct Answer

B — Alpha-1-mediated blood pressure elevation activates baroreceptors, triggering compensatory vagal slowing of the sinoatrial node

Rationale

Norepinephrine's strong alpha-1 receptor activity causes marked peripheral vasoconstriction and a significant rise in systolic and diastolic blood pressure. This pressure elevation is sensed by arterial baroreceptors in the carotid sinus and aortic arch, which send afferent signals to brainstem cardiovascular centers. The homeostatic response is an increase in parasympathetic (vagal) tone to the sinoatrial node, slowing spontaneous depolarization and reducing heart rate. This reflex bradycardia is particularly pronounced with norepinephrine because it lacks the beta-2 vasodilatory activity of epinephrine that would otherwise blunt the blood pressure rise and reduce baroreceptor activation. Muscarinic receptor activation is the mechanism of parasympathetic bradycardia, not a direct action of norepinephrine. Beta-1 receptor blockade would slow the heart differently from the baroreceptor reflex. Beta-2 sinoatrial node activity is minimal with norepinephrine compared with epinephrine.

Correct Answer

D — Alpha-1-mediated aortic vasoconstriction, raising coronary perfusion pressure during cardiopulmonary resuscitation

Rationale

During cardiac arrest, the heart receives coronary blood flow primarily during the diastolic phase of cardiopulmonary resuscitation compressions. Coronary perfusion pressure is determined by the aortic diastolic pressure minus the right atrial pressure. Epinephrine's alpha-1-mediated vasoconstriction raises aortic diastolic pressure, increasing coronary perfusion pressure and improving the likelihood of successful defibrillation. This mechanism — not direct cardiac stimulation — is the primary benefit of epinephrine in cardiac arrest, as supported by the PARAMEDIC2 trial. Beta-1 effects become relevant to hemodynamic recovery after return of spontaneous circulation rather than during the arrest itself. Beta-2 bronchodilation plays no meaningful role in cardiac resuscitation. Alpha-2 receptor activation reduces sympathetic tone — the opposite of what is needed during cardiac arrest.

Correct Answer

A — Activation of alpha-2A receptors in the locus coeruleus produces sedation from which patients are easily aroused without respiratory depression

Rationale

Dexmedetomidine is a highly selective alpha-2 agonist that acts primarily at alpha-2A receptors in the locus coeruleus, the brainstem's primary noradrenergic nucleus. Reduced noradrenergic output from the locus coeruleus produces a sedative state that mimics natural sleep — patients are calm, cooperative, and arousable to voice or light stimulation. At standard doses, dexmedetomidine does not cause respiratory depression, which makes it particularly useful when the clinical team needs to assess neurological status without fully interrupting sedation. This property distinguishes it from gamma-aminobutyric acid-based agents such as propofol and benzodiazepines. The alpha-2 agonist mechanism of dexmedetomidine is pharmacologically distinct from the Gs-coupled signaling of beta agonists, the chloride channel potentiation of gamma-aminobutyric acid agents, and the G-protein-coupled inhibitory signaling of opioid analgesics.

Correct Answer

C — Add an inhaled corticosteroid controller therapy, as frequent rescue inhaler use indicates inadequate asthma control

Rationale

Albuterol is a short-acting beta-2 agonist indicated for rescue bronchodilation. Use more than twice per week is a recognized threshold indicating inadequate asthma control — the underlying airway inflammation is not being managed, and the patient is relying on symptomatic relief rather than disease control. The appropriate pharmacological response is to add an inhaled corticosteroid as controller therapy, which addresses the underlying inflammatory pathology. Salmeterol is a long-acting beta-2 agonist that must never be used as monotherapy without an inhaled corticosteroid in asthma — increased asthma-related mortality with salmeterol alone was demonstrated in the SMART trial. Increasing the albuterol dose does not address the underlying airway inflammation. Oral beta-2 agonists produce a worse systemic adverse effect profile than inhaled formulations.

Correct Answer

D — Epinephrine, which simultaneously reverses vasodilation through alpha-1 agonism, supports cardiac output through beta-1 agonism, and reverses bronchospasm through beta-2 agonism

Rationale

Anaphylaxis is a life-threatening multisystem reaction requiring a drug that addresses every component simultaneously. Epinephrine is the only agent with this profile: alpha-1 activation reverses vasodilation and angioedema, beta-1 activation maintains cardiac output against the falling blood pressure, and beta-2 activation reverses bronchospasm and inhibits further mast cell mediator release. No other single agent matches this combination. Diphenhydramine blocks histamine receptors but does not reverse hemodynamic collapse or bronchospasm rapidly enough to serve as first-line treatment. Norepinephrine lacks meaningful beta-2 activity and cannot adequately reverse bronchospasm. Albuterol addresses bronchospasm but has minimal vasopressor activity and cannot reverse the circulatory collapse.

Correct Answer

B — Alpha-1-mediated peripheral vasoconstriction, increasing systemic vascular resistance and raising mean arterial pressure

Rationale

The pathophysiology of septic shock is distributive — massive peripheral vasodilation from inflammatory mediators causes a low systemic vascular resistance state with an inappropriately low mean arterial pressure despite a normal or elevated cardiac output. The primary therapeutic need is restoration of vascular tone. Norepinephrine, the guideline-recommended first-line vasopressor, accomplishes this through potent alpha-1-mediated peripheral vasoconstriction, raising systemic vascular resistance and restoring mean arterial pressure to target levels above 65 mmHg. Its additional beta-1 activity provides modest cardiac support without the arrhythmia burden of dopamine. Dobutamine increases cardiac output through inotropic support but does not restore vascular tone in distributive shock. Low-dose dopamine addresses renal vasodilation rather than the systemic hypotension that defines septic shock. Beta-2 receptor activation produces vasodilation, which would worsen rather than correct the distributive pathophysiology.

Correct Answer

A — Beta-1 receptor activation raises intracellular cyclic adenosine monophosphate, enhancing calcium availability and increasing myocardial contractility

Rationale

Dobutamine is the preferred inotropic agent for low-output cardiogenic shock when blood pressure is maintained. It acts primarily on beta-1 receptors in myocardial cells, activating Gs-coupled adenylyl cyclase to increase cyclic adenosine monophosphate. Elevated cyclic adenosine monophosphate activates protein kinase A, which phosphorylates L-type calcium channels, increasing calcium entry during systole and enhancing contractile force. The mild beta-2 vasodilatory activity of dobutamine also reduces afterload, further improving cardiac output. Alpha-1 receptor activation in the myocardium has minimal inotropic relevance compared with beta-1 stimulation. Dopamine-1 renal vasodilation does not meaningfully improve cardiac output in low-output states. Alpha-2 brainstem activation describes the mechanism of clonidine and dexmedetomidine — central sympatholytics rather than inotropic agents.

Correct Answer

C — Long-acting beta-2 agonists provide symptom relief without treating underlying airway inflammation, masking worsening disease and increasing the risk of fatal exacerbations

Rationale

The SMART trial demonstrated that salmeterol monotherapy in asthma was associated with a significant increase in asthma-related deaths compared with placebo. The mechanistic explanation is that long-acting beta-2 agonists produce sustained bronchodilation — providing subjective relief from symptoms — without addressing the underlying eosinophilic airway inflammation that is the pathological substrate of asthma. Patients feel better and may not recognize the progressive deterioration in airway inflammation beneath the bronchodilatory effect. When an exacerbation does occur, it can be both more severe and less responsive to rescue therapy because the inflammatory process has been unchecked. Inhaled corticosteroids must always accompany long-acting beta-2 agonist use in asthma to suppress the inflammatory component. Salmeterol does not irreversibly bind receptors — its prolonged duration of action reflects lipophilicity and receptor binding kinetics rather than covalent attachment. Salmeterol has no alpha-1 receptor activity. The premise that salmeterol inhibits anti-inflammatory cytokines has no pharmacological basis.